The latest financial statement is for the year ending 2025-12-31.
| Cash Flow | 2025-12-31 |
|---|---|
| Total revenues | 718,952 |
| Cost of revenues | 74,562 |
| Selling | 209,695 |
| Marketing | 78,956 |
| General and administrative | 123,987 |
| Acquisition-related expenses | 72,925 |
| ONAPGO | 1,883 |
| SPN820 | 10,075 |
| SPN817 | 15,727 |
| Qelbree | 11,411 |
| ZURZUVAE | 2,145 |
| Early Stage Program And Other | 20,926 |
| Total external development program expenses | 62,167 |
| Internal employee-related expenses | 44,068 |
| Total research and development expenses | 106,235 |
| Other segment items | 91,142 |
| Net earnings (loss) | -38,550 |
| Depreciation and amortization | 91,563 |
| Intangible asset impairment charges | 0 |
| Amortization of deferred financing costs and debt discount | 0 |
| Realized loss (gains) from sales of marketable securities | -439 |
| Amortization of premium/discount on marketable securities | 1,529 |
| Change in fair value of contingent consideration | 25,419 |
| Share-based compensation expense | 33,051 |
| Deferred income tax benefit | 5,206 |
| Inventory valuation write-down | 1,926 |
| Payment of contingent consideration | 4,900 |
| Noncash lease expense | 7,980 |
| Other noncash adjustments, net | -1,885 |
| Accounts receivable | 22,304 |
| Inventories | 7,502 |
| Prepaid expenses and other assets | 13,179 |
| Accrued product returns and rebates | -7,608 |
| Accounts payable and other liabilities | -24,566 |
| Net cash provided by operating activities | 47,331 |
| Acquisition of sage, net of cash acquired | 293,093 |
| Purchases of marketable securities | 475,941 |
| Maturities of marketable securities | 774,478 |
| Purchases of property and equipment | 1,338 |
| Net cash provided by (used in) investing activities | 4,106 |
| Proceeds from credit line | 0 |
| Payments on credit line | 0 |
| Payment on convertible notes | 0 |
| Proceeds from issuance of common stock | 37,616 |
| Employee taxes paid related to net share settlement of equity awards | 4,229 |
| Payment of contingent consideration | 24,257 |
| Net cash provided by (used in) financing activities | 9,130 |
| Net change in cash, cash equivalents, and restricted cash | 60,567 |
| Cash and cash equivalents at beginning of year | 69,331 |
| Cash, cash equivalents, and restricted cash at end of year | 129,898 |
SUPERNUS PHARMACEUTICALS, INC. (SUPN)
SUPERNUS PHARMACEUTICALS, INC. (SUPN)